MCP: How radiotherapies
vanquish cancer cells
Tumor-shredding therapies aren't created equal. When someone with cancer decides to treat the cellular aberration with radiation therapy, as more than 50 percent of cancer patients now do, their primary options are X-rays or particle beams. Despite being available at only a handful of treatment centers worldwide, particle beams, which use protons or carbon ions, possess a number of benefits over traditional X-rays.
The effects of the beams on the mechanisms that govern signaling within cells remain largely unexplored. A recent paper in the journal sheds some light on this matter.
To better understand the regulatory effects that the particle-based techniques have on the structure and signaling pathways of cancerous cells, researchers at the and applied a combination of high-resolution mass spectrometry and SILAC to irradiated human lung adenocarcinoma cells. SILAC is short for stable isotope labeling by amino acids in cell culture; by incorporating amino acids labeled with heavy isotopes into cell cultures and comparing those cells’ mass spectrometry peaks to those of identical, untreated cell cultures, researchers can examine the effects of an outside agent, such as radiation, on the protein makeup of a culture.
“The research interest is just finding out what radiation is doing to cells, to humans and to tissues,” says senior author at the center’s Functional Proteome Analysis unit. “As a chemist, it was really interesting to work together with the radiation oncologists, because my background is more proteomics and not medicine.”
Whereas X-rays destroy cancer cells by inflicting strand breaks on DNA’s double-helix structure, which can be fixed by DNA repair mechanisms, protons and carbon ions tear the genetic structure apart with complex double-strand breaks, which cannot be repaired. This gives proton and carbon ion beams a larger relative biological effectiveness than X-rays, meaning they kill more cancer cells than X-rays do at the same dose. Additionally, particle beams deposit their energy in a more focused manner than X-rays, damaging to a lesser extent the healthy tissues surrounding tumors.
The researchers separated cultures of the human lung cancer cell line into two groups that were fed amino acids with heavy isotopes or light isotopes and irradiated subgroups of the heavy-labeled cells with x-rays, carbon ions or protons. They then performed a phosphopeptide enrichment to increase the concentration of phosphorylated proteins in each sample before subjecting the cells to mass spectrometry to identify changes that had occurred at the protein structure level and which sites had phosphate molecules added or removed. The addition or removal of these molecules is a key indicator that cells are attempting to mitigate damage and is known in aggregate as the phosphoproteome.
While the researchers observed only limited effects on lung cells at the protein level, they noticed altered phosphorylation regulation on 181 different protein sites, or residues, 151 of which had not been previously been known to be affected by irradiation.
“We’ve looked at differential quantification of the proteins and found that there is little happening as an initial event as a consequence of radiation, whereas the phosphoproteome is massively (dysregulated),” says senior co-author at the center’s Division for ͵͵ and Translational Radiation Oncology. This information will be helpful for designing future studies that examine the effects of radiotherapy, ionizing radiation and space radiation on cellular signaling processes, he says.
Future work for Schnölzer and Abdollahi will involve looking at the effects of radiation on a longer timescale to understand late effects of irradiation and examining its effects on pathways other than phosphorylation signaling.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.